Teva Pharmaceutical Industries Ltd., announced the launch of the generic equivalent to CAMPRAL®1 (acamprosate calcium) delayed-release tablets, 333 mg, in the United States. Acamprosate calcium delayed-release tablets are used for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at the start of treatment.
Treatment with acamprosate calcium delayed-release tablets helps maintain abstinence from alcohol only when used as part of a treatment program that includes counseling and support.
Acamprosate calcium delayed-release tablets had annual sales of approximately $14 million in the United States, according to IMS data as of December 2015.
